+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Benexate Market by Product Type (Injectable Solutions, Oral Tablets, Topical Ointments), Application (Acute Pain Management, Chronic Pain Management, Neuropathic Pain), Distribution Channel, End-user, Therapeutic Class, Treatment Duration - Global Forecast 2025-2030- Product Image
Benexate Market by Product Type (Injectable Solutions, Oral Tablets, Topical Ointments), Application (Acute Pain Management, Chronic Pain Management, Neuropathic Pain), Distribution Channel, End-user, Therapeutic Class, Treatment Duration - Global Forecast 2025-2030- Product Image
Sale

Benexate Market by Product Type (Injectable Solutions, Oral Tablets, Topical Ointments), Application (Acute Pain Management, Chronic Pain Management, Neuropathic Pain), Distribution Channel, End-user, Therapeutic Class, Treatment Duration - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • November 2024
  • Region: Global
  • 360iResearch™
  • ID: 6013774
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Benexate Market grew from USD 549.34 million in 2023 to USD 584.38 million in 2024. It is expected to continue growing at a CAGR of 6.85%, reaching USD 873.82 million by 2030.

Benexate, a pharmacological compound primarily used in anti-ulcer medications, holds significant potential in the pharmaceutical industry. The scope involves its formulation and commercialization in treating gastric ailments. The necessity arises from the increasing prevalence of peptic ulcer disease and the consumer demand for more efficient and less invasive treatment options. Applications extend to its use in both over-the-counter and prescription medications, with end-use spanning hospitals, clinics, and retail pharmacies globally. Key influencing growth factors include a rising geriatric population, technological advancements in drug delivery systems, and increasing healthcare expenditure in emerging markets.

Opportunities abound in expanding partnerships with healthcare providers to enhance drug accessibility and investing in research and development for improved benexate formulations. Market insights indicate that strategic market penetration in Asia-Pacific regions, where the prevalence of gastric diseases is higher, can yield substantial growth. However, challenges such as stringent regulatory frameworks, potential side effects, and competition from alternative therapies may impede market expansion. Regulatory hurdles pertaining to drug approval and patent expiration can present barriers to new market entrants.

Innovation is crucial, with potential areas including the development of benexate with enhanced bioavailability or its incorporation into combination therapies to target multi-symptom disorders. Emphasis on patient-centered care and personalized medicine can drive growth and offer a competitive edge. The market is characterized by rapid technological advancements and a push towards sustainable practices, which call for continuous innovation to maintain relevance and competitiveness.

As the demand for effective and convenient ulcer treatments rises, leveraging cutting-edge research to diversify benexate applications and formulations could ensure sustained market presence and growth. To maximize potential, strategic collaborations and targeted investments in research innovation are recommended to navigate the competitive landscape and address market challenges.

Understanding Market Dynamics in the Benexate Market

The Benexate Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Strategic collaborations and partnerships among pharmaceutical companies enhancing market reach.
    • Increased research and development activities fostering innovation in gastrointestinal therapies.
    • Increasing prevalence of gastritis and peptic ulcers driving higher demand for Benexate.
  • Market Restraints
    • Highlighting intellectual property considerations limiting innovation strategies for Benexate
    • Investigating regulatory and compliance challenges restraining Benexate's market accessibility
    • Evaluating supply chain and distribution hurdles affecting the availability of Benexate
  • Market Opportunities
    • Customizing Benexate offerings for pediatric use to capture an untapped segment in therapeutics
    • Developing educational workshops for healthcare professionals to raise awareness about Benexate
    • Introducing subscription models for Benexate to ensure consistent and reliable customer loyalty
  • Market Challenges
    • Limited consumer awareness impedes market penetration and adoption of Benexate products
    • High production and operational costs affecting Benexate profit margins and pricing strategies
    • Economic downturns influence consumer purchasing power for premium Benexate products

Exploring Porter’s Five Forces for the Benexate Market

Porter’s Five Forces framework further strengthens the insights of the Benexate Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Benexate Market

External macro-environmental factors deeply influence the performance of the Benexate Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Benexate Market

The Benexate Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Benexate Market

The Benexate Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Benexate Market

The Benexate Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Benexate Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Meiji Seika Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Nichi-Iko Pharmaceutical Co., Ltd., Nipro Corporation, Otsuka Pharmaceutical Co., Ltd., Sawai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, and Towa Pharmaceutical Co., Ltd.

Market Segmentation & Coverage

This research report categorizes the Benexate Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product Type
    • Injectable Solutions
      • Pre-Filled Syringes
      • Vials
    • Oral Tablets
      • Extended-Release
      • Immediate-Release
    • Topical Ointments
      • Cream-Based
      • Gel-Based
      • Patch-Based
  • Application
    • Acute Pain Management
      • Injury-Induced Pain
      • Post-Surgical Pain
    • Chronic Pain Management
      • Arthritis Pain
      • Back Pain
      • Cancer Pain
    • Neuropathic Pain
      • Diabetic Neuropathy
      • Post-Herpetic Neuralgia
  • Distribution Channel
    • Hospitals
      • Private Hospitals
      • Public Hospitals
    • Online Pharmacies
      • E-Pharma Platforms
    • Retail Pharmacies
      • Chain Pharmacies
      • Independent Pharmacies
  • End User
    • Adults
      • Elderly Population
      • Working Professionals
    • Pediatric
      • Children
      • Infants
  • Therapeutic Class
    • Analgesics
    • Antipyretics
  • Treatment Duration
    • Long-Term Therapy
    • Short-Term Therapy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States (California, Florida, Illinois, New York, Ohio, Pennsylvania, Texas)
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  • Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  • Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  • Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  • Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  • Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  • What is the current size of the market, and how is it expected to grow?
  • Which products, segments, and regions present the most attractive investment opportunities?
  • What are the prevailing technology trends and regulatory factors influencing the market?
  • How do top vendors rank regarding market share and competitive positioning?
  • What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Strategic collaborations and partnerships among pharmaceutical companies enhancing market reach.
5.1.1.2. Increased research and development activities fostering innovation in gastrointestinal therapies.
5.1.1.3. Increasing prevalence of gastritis and peptic ulcers driving higher demand for Benexate.
5.1.2. Restraints
5.1.2.1. Highlighting intellectual property considerations limiting innovation strategies for Benexate
5.1.2.2. Investigating regulatory and compliance challenges restraining Benexate's market accessibility
5.1.2.3. Evaluating supply chain and distribution hurdles affecting the availability of Benexate
5.1.3. Opportunities
5.1.3.1. Customizing Benexate offerings for pediatric use to capture an untapped segment in therapeutics
5.1.3.2. Developing educational workshops for healthcare professionals to raise awareness about Benexate
5.1.3.3. Introducing subscription models for Benexate to ensure consistent and reliable customer loyalty
5.1.4. Challenges
5.1.4.1. Limited consumer awareness impedes market penetration and adoption of Benexate products
5.1.4.2. High production and operational costs affecting Benexate profit margins and pricing strategies
5.1.4.3. Economic downturns influence consumer purchasing power for premium Benexate products
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Benexate Market, by Product Type
6.1. Introduction
6.2. Injectable Solutions
6.2.1. Pre-Filled Syringes
6.2.2. Vials
6.3. Oral Tablets
6.3.1. Extended-Release
6.3.2. Immediate-Release
6.4. Topical Ointments
6.4.1. Cream-Based
6.4.2. Gel-Based
6.4.3. Patch-Based
7. Benexate Market, by Application
7.1. Introduction
7.2. Acute Pain Management
7.2.1. Injury-Induced Pain
7.2.2. Post-Surgical Pain
7.3. Chronic Pain Management
7.3.1. Arthritis Pain
7.3.2. Back Pain
7.3.3. Cancer Pain
7.4. Neuropathic Pain
7.4.1. Diabetic Neuropathy
7.4.2. Post-Herpetic Neuralgia
8. Benexate Market, by Distribution Channel
8.1. Introduction
8.2. Hospitals
8.2.1. Private Hospitals
8.2.2. Public Hospitals
8.3. Online Pharmacies
8.3.1. E-Pharma Platforms
8.4. Retail Pharmacies
8.4.1. Chain Pharmacies
8.4.2. Independent Pharmacies
9. Benexate Market, by End User
9.1. Introduction
9.2. Adults
9.2.1. Elderly Population
9.2.2. Working Professionals
9.3. Pediatric
9.3.1. Children
9.3.2. Infants
10. Benexate Market, by Therapeutic Class
10.1. Introduction
10.2. Analgesics
10.3. Antipyretics
11. Benexate Market, by Treatment Duration
11.1. Introduction
11.2. Long-Term Therapy
11.3. Short-Term Therapy
12. Americas Benexate Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Benexate Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Benexate Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. BENEXATE MARKET MULTI-CURRENCY
FIGURE 2. BENEXATE MARKET MULTI-LANGUAGE
FIGURE 3. BENEXATE MARKET RESEARCH PROCESS
FIGURE 4. BENEXATE MARKET SIZE, 2023 VS 2030
FIGURE 5. GLOBAL BENEXATE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL BENEXATE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BENEXATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BENEXATE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BENEXATE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BENEXATE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL BENEXATE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
FIGURE 17. GLOBAL BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2023 VS 2030 (%)
FIGURE 19. GLOBAL BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. AMERICAS BENEXATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. AMERICAS BENEXATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. UNITED STATES BENEXATE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 23. UNITED STATES BENEXATE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ASIA-PACIFIC BENEXATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. ASIA-PACIFIC BENEXATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BENEXATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA BENEXATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. BENEXATE MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 29. BENEXATE MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BENEXATE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BENEXATE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BENEXATE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BENEXATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BENEXATE MARKET DYNAMICS
TABLE 7. GLOBAL BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BENEXATE MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BENEXATE MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BENEXATE MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BENEXATE MARKET SIZE, BY EXTENDED-RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BENEXATE MARKET SIZE, BY IMMEDIATE-RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BENEXATE MARKET SIZE, BY CREAM-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BENEXATE MARKET SIZE, BY GEL-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BENEXATE MARKET SIZE, BY PATCH-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BENEXATE MARKET SIZE, BY INJURY-INDUCED PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BENEXATE MARKET SIZE, BY POST-SURGICAL PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BENEXATE MARKET SIZE, BY ARTHRITIS PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BENEXATE MARKET SIZE, BY BACK PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BENEXATE MARKET SIZE, BY CANCER PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BENEXATE MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BENEXATE MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BENEXATE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BENEXATE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BENEXATE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BENEXATE MARKET SIZE, BY E-PHARMA PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BENEXATE MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BENEXATE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BENEXATE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BENEXATE MARKET SIZE, BY ELDERLY POPULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BENEXATE MARKET SIZE, BY WORKING PROFESSIONALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BENEXATE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BENEXATE MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BENEXATE MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BENEXATE MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BENEXATE MARKET SIZE, BY ANTIPYRETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BENEXATE MARKET SIZE, BY LONG-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BENEXATE MARKET SIZE, BY SHORT-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BENEXATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 114. CANADA BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. CANADA BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 116. CANADA BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 117. CANADA BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 118. CANADA BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. CANADA BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 120. CANADA BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 121. CANADA BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 122. CANADA BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. CANADA BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 124. CANADA BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 125. CANADA BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 126. CANADA BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. CANADA BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 128. CANADA BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 129. CANADA BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 130. CANADA BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 131. MEXICO BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 132. MEXICO BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 133. MEXICO BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 134. MEXICO BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 135. MEXICO BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. MEXICO BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 137. MEXICO BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 138. MEXICO BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 139. MEXICO BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. MEXICO BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 142. MEXICO BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 143. MEXICO BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. MEXICO BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 145. MEXICO BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 146. MEXICO BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 147. MEXICO BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES BENEXATE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC BENEXATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 185. AUSTRALIA BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 201. CHINA BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 202. CHINA BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 203. CHINA BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 204. CHINA BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 205. CHINA BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 206. CHINA BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 207. CHINA BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 208. CHINA BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 209. CHINA BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. CHINA BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 211. CHINA BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 212. CHINA BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 213. CHINA BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. CHINA BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 215. CHINA BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 216. CHINA BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 217. CHINA BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 218. INDIA BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. INDIA BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 220. INDIA BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 221. INDIA BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 222. INDIA BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. INDIA BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 224. INDIA BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 225. INDIA BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 226. INDIA BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. INDIA BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 228. INDIA BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 229. INDIA BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 230. INDIA BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. INDIA BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 232. INDIA BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 233. INDIA BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 234. INDIA BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 235. INDONESIA BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 236. INDONESIA BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 237. INDONESIA BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 238. INDONESIA BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 251. INDONESIA BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 252. JAPAN BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 253. JAPAN BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 254. JAPAN BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 255. JAPAN BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 256. JAPAN BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 257. JAPAN BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 258. JAPAN BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 259. JAPAN BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 260. JAPAN BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. JAPAN BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 262. JAPAN BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 263. JAPAN BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 264. JAPAN BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. JAPAN BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 266. JAPAN BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 267. JAPAN BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 268. JAPAN BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 269. MALAYSIA BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 270. MALAYSIA BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 271. MALAYSIA BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 272. MALAYSIA BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 273. MALAYSIA BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 274. MALAYSIA BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 275. MALAYSIA BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 276. MALAYSIA BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 277. MALAYSIA BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. MALAYSIA BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 279. MALAYSIA BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 280. MALAYSIA BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 281. MALAYSIA BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. MALAYSIA BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 283. MALAYSIA BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 284. MALAYSIA BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 285. MALAYSIA BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 286. PHILIPPINES BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 287. PHILIPPINES BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 298. PHILIPPINES BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. PHILIPPINES BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 300. PHILIPPINES BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 301. PHILIPPINES BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 302. PHILIPPINES BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 303. SINGAPORE BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 304. SINGAPORE BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 305. SINGAPORE BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 306. SINGAPORE BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 307. SINGAPORE BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 308. SINGAPORE BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 309. SINGAPORE BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 311. SINGAPORE BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 312. SINGAPORE BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 313. SINGAPORE BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 314. SINGAPORE BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 315. SINGAPORE BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. SINGAPORE BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 317. SINGAPORE BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 318. SINGAPORE BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 319. SINGAPORE BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 320. SOUTH KOREA BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 321. SOUTH KOREA BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 322. SOUTH KOREA BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 323. SOUTH KOREA BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 324. SOUTH KOREA BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 325. SOUTH KOREA BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 326. SOUTH KOREA BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 327. SOUTH KOREA BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 328. SOUTH KOREA BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 329. SOUTH KOREA BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 330. SOUTH KOREA BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 331. SOUTH KOREA BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 332. SOUTH KOREA BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 333. SOUTH KOREA BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 334. SOUTH KOREA BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 335. SOUTH KOREA BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 336. SOUTH KOREA BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 337. TAIWAN BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 338. TAIWAN BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 339. TAIWAN BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 340. TAIWAN BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 341. TAIWAN BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 342. TAIWAN BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 343. TAIWAN BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 344. TAIWAN BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 345. TAIWAN BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 346. TAIWAN BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 347. TAIWAN BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 348. TAIWAN BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 349. TAIWAN BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 350. TAIWAN BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 351. TAIWAN BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 352. TAIWAN BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 353. TAIWAN BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 354. THAILAND BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 355. THAILAND BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 356. THAILAND BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 357. THAILAND BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 358. THAILAND BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 359. THAILAND BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 360. THAILAND BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 361. THAILAND BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 362. THAILAND BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 363. THAILAND BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 364. THAILAND BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 365. THAILAND BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 366. THAILAND BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 367. THAILAND BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 368. THAILAND BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 369. THAILAND BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 370. THAILAND BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 371. VIETNAM BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 372. VIETNAM BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 373. VIETNAM BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 374. VIETNAM BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 375. VIETNAM BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 376. VIETNAM BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 377. VIETNAM BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 378. VIETNAM BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 379. VIETNAM BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 380. VIETNAM BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 381. VIETNAM BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2

Companies Mentioned

  • Astellas Pharma Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Kyowa Kirin Co., Ltd.
  • Meiji Seika Pharma Co., Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Nipro Corporation
  • Otsuka Pharmaceutical Co., Ltd.
  • Sawai Pharmaceutical Co., Ltd.
  • Shionogi & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited
  • Towa Pharmaceutical Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages193
PublishedNovember 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 584.38 million
Forecasted Market Value ( USD ) by 2030 $ 873.82 million
Compound Annual Growth Rate6.8%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Benexate (CAS 78718-52-2) Global Market Research Report 2024 - Product Image

Benexate (CAS 78718-52-2) Global Market Research Report 2024

  • Report
  • 50 Pages
  • Global
From
Diisopromine Market by Application, End User, Drug Form, Distribution Channel, Therapeutic Area - Global Forecast 2025-2030 - Product Image

Diisopromine Market by Application, End User, Drug Form, Distribution Channel, Therapeutic Area - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Opioid Induced Constipation Market by Active Ingredients, Drug Class, Mode of Administration, Distribution Channel - Global Forecast 2025-2030 - Product Image

Opioid Induced Constipation Market by Active Ingredients, Drug Class, Mode of Administration, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
U.S. Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report by Type, Drug Class, Route Of Administration, Distribution Channel, Region, and Segment Forecasts, 2024-2030 - Product Image

U.S. Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report by Type, Drug Class, Route Of Administration, Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • 70 Pages
  • United States
From

About the Benexate Market

Benexate is a medication used to treat gastrointestinal disorders. It is a proton pump inhibitor, meaning it reduces the amount of acid produced in the stomach. It is used to treat conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. It is also used to prevent stomach ulcers caused by certain medications. Benexate is available in both prescription and over-the-counter forms. Benexate is one of many medications used to treat gastrointestinal disorders. Other medications include antacids, H2 blockers, and prokinetics. These medications work in different ways to reduce stomach acid and treat symptoms of gastrointestinal disorders. The Benexate market is highly competitive, with many companies offering similar products. Some of the companies in the market include AstraZeneca, Pfizer, GlaxoSmithKline, Merck, and Novartis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.